<DOC>
	<DOC>NCT01574235</DOC>
	<brief_summary>The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.</brief_summary>
	<brief_title>Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
	<criteria>Age ≥ 18 years Patients presenting with a solid tumor or a malignant hemopathy, Patients treated with or beginning treatment with neutropeniainducing chemotherapy (regardless of the cycle), Patients in whom treatment with Nivestim® is instituted for the purpose of reducing the duration of the neutropenias and the incidence of the chemotherapyinduced febrile neutropenias Patients presenting with a chronic myeloproliferative syndrome, Patients presenting with a myelodysplastic syndrome, Patients showing hypersensitivity to any of the ingredients of Nivestim®, Patients not receiving chemotherapy, Patients who were already included in the study during a previous chemotherapy line</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>